The FDA has approved a supplemental new drug application from Omeros to expand the indication for Omidria for use in pediatric patients, according to a company press release.
Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution) prevents intraoperative miosis and reduces postoperative pain during cataract surgery or IOL replacement.
In addition to expanding the drug’s indication, the FDA also granted an additional 6 months of U.S. market exclusivity for Omidria, the release said.
“Now all patients undergoing cataract or other lens replacement surgery can receive the
Uncategorized